Biogen and California biotech Sangamo Therapeutics have announced a global licensing collaboration agreement to develop and commercialize ST-501 for tauopathies including Alzheimer’s disease, ST-502 for synucleinopathies including Parkinson’s disease, a third undisclosed neuromuscular disease target, and up to nine additional undisclosed neurological disease targets. The companies will leverage Sangamo’s proprietary zinc finger protein (ZFP) technology […]

Bicycle Therapeutics has announced a strategic collaboration agreement with Genentech to discover, develop and commercialize novel immuno-oncology therapies. Bicycle is headquartered in Cambridge, UK with many key functions and members of its leadership team located in Lexington, MA. By entering into this early discovery collaboration with Genentech, Bicycle will be exploring its technology on a […]

Moderna scientists designed the prophylactic vaccines modality to prevent infectious diseases. More than 1,000 participants have been enrolled in Moderna’s infectious disease vaccine clinical studies under health authorities in the U.S., Europe and Australia. Based on clinical experience across six Phase 1 studies, the Company has designated prophylactic vaccines a core modality and intends to […]

Moderna has released the first batch of mRNA-1273, its vaccine against the novel coronavirus identified as the cause of pneumonia cases in Wuhan, China. Vials of mRNA-1273 have been shipped to the National Institute of Allergy and Infectious Diseases (NIAID) to be used in the planned Phase 1 study in the U.S. mRNA-1273 is an […]

Beam Therapeutics has announced aggregate gross proceeds of $207 million from their initial public offering which closed on February 11. Beam is a biotechnology company developing precision genetic medicines through the use of base editing. According to their website, Beam’s proprietary base editors create precise, predictable and efficient single base changes, at targeted genomic sequences, […]

Merck has announced plans to spin-off products from its women’s health, legacy brands and biosimilars businesses into a new, independent, publicly-traded company (NewCo). Merck will continue to benefit from strong growth across its current key pillars of oncology, vaccines, hospital and animal health, while remaining fully committed to investing in R&D and to driving value […]